Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study - PubMed (original) (raw)
Clinical Trial
. 2010 Apr;37(4):299-310.
doi: 10.1111/j.1346-8138.2009.00748.x.
Collaborators, Affiliations
- PMID: 20507398
- DOI: 10.1111/j.1346-8138.2009.00748.x
Clinical Trial
Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study
Akihiko Asahina et al. J Dermatol. 2010 Apr.
Abstract
Incidence of psoriasis vulgaris in Asians is estimated at 0.05-0.3%. Studies in North America and Europe demonstrated that adalimumab, a fully human, recombinant, immunoglobulin G(1) monoclonal antibody, was efficacious and well-tolerated in patients with chronic plaque psoriasis. This 24-week, placebo-controlled study evaluated the efficacy and safety of three different dosing regimens of adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis (n = 169). Patients were randomized to receive adalimumab 40 mg every other week (eow), adalimumab 80-mg loading dose at week 0 followed by adalimumab 40 mg eow starting at week 2, adalimumab 80 mg eow, or placebo eow given as s.c. injections. The primary efficacy endpoint was the percentage of patients achieving a 75% or greater improvement in Psoriasis Area and Severity Index (PASI 75) score at week 16. At week 16, PASI 75 response rates were significantly greater for all three adalimumab groups (40 mg eow: 57.9%, P < 0.001; 40 mg eow plus loading dose: 62.8%, P < 0.001; 80 mg eow: 81.0%, P < 0.001) versus placebo (4.3%). As early as week 4, the 40-mg eow plus loading dose and 80-mg eow groups achieved significantly greater PASI 75 response rates compared with placebo. Injection-site reactions and hepatic events occurred in greater percentages of adalimumab-treated patients compared with placebo. Adalimumab therapy demonstrated efficacy and safety at all three dosage regimens. Rapid response rate in patients receiving 40 mg eow plus loading dose supports using an 80-mg loading dose in the treatment of psoriasis.
Similar articles
- Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, Gu Y, Okun MM. Leonardi C, et al. Br J Dermatol. 2012 Sep;167(3):658-67. doi: 10.1111/j.1365-2133.2012.11041.x. Epub 2012 Aug 20. Br J Dermatol. 2012. PMID: 22564148 Clinical Trial. - Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J. Leonardi C, et al. Arch Dermatol. 2011 Apr;147(4):429-36. doi: 10.1001/archdermatol.2010.384. Epub 2010 Dec 20. Arch Dermatol. 2011. PMID: 21173304 Clinical Trial. - A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.
Vena GA, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pità O, Pezza M, D Agostino M, Vernaci R, Miracapillo A, Valenti G, Cassano N. Vena GA, et al. Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):227-33. doi: 10.1177/039463200902200125. Int J Immunopathol Pharmacol. 2009. PMID: 19309570 - Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Ahn CS, et al. Am J Clin Dermatol. 2013 Aug;14(4):315-26. doi: 10.1007/s40257-013-0030-z. Am J Clin Dermatol. 2013. PMID: 23696234 Review. - Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies.
Papp K, Okun M, Vender R. Papp K, et al. J Cutan Med Surg. 2009 Sep-Oct;13 Suppl 2:S58-66. doi: 10.2310/7750.2009.00022. J Cutan Med Surg. 2009. PMID: 19799828 Review.
Cited by
- Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW, Warren RB, Zhong Y, Zhuo J, Cichewicz A, Kadambi A, Junqueira D, Westley T, Kisa R, Daamen C, Augustin M. Armstrong AW, et al. Dermatol Ther (Heidelb). 2023 Nov;13(11):2839-2857. doi: 10.1007/s13555-023-01034-7. Epub 2023 Oct 6. Dermatol Ther (Heidelb). 2023. PMID: 37801281 Free PMC article. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. Cochrane Database Syst Rev. 2023. PMID: 37436070 Free PMC article. Review. - Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis.
Golhen K, Winskill C, Theiler M, Buettcher M, Yeh YH, Zhang N, Welzel T, Pfister M. Golhen K, et al. Front Med (Lausanne). 2022 Sep 26;9:944208. doi: 10.3389/fmed.2022.944208. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36226155 Free PMC article. Review. - Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Feng Y, Zhou B, Wang Z, Xu G, Wang L, Zhang T, Zhang Y. Feng Y, et al. Int J Clin Pract. 2022 Sep 21;2022:2442603. doi: 10.1155/2022/2442603. eCollection 2022. Int J Clin Pract. 2022. PMID: 36212052 Free PMC article. Review. - Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour.
Lytvyn Y, Sachdeva M, Mufti A, Yeung J. Lytvyn Y, et al. Drugs Context. 2022 May 31;11:2021-9-3. doi: 10.7573/dic.2021-9-3. eCollection 2022. Drugs Context. 2022. PMID: 35720056 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials